Ms. Nisa LEUNG, MH, JP
Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 530 portfolio companies.
She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan & Lee (SSE:603087), Venus MedTech (HKSE:2500), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR) , Recursion (NASDAQ:RXRX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.
Nisa has been recognized by the Forbes Midas List for five consecutive years in 2019, 2020, 2021, 2022 and 2023, and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021) and Most Powerful Women in Business by Fortune China in 2022.
She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University.